Γ

SynBioBeta Speaker

Gabriele Corso

Boltz

CEO

Gabriele received his PhD from MIT CSAIL where his research focused on developing novel ML frameworks to tackle challenging problems in drug discovery and he led the development of popular models in the space including DiffDock, Boltz-1 and Boltz-2.

Sessions Featuring

Gabriele

This Year

Breakout Session

3:30 PM

-

4:15 PM

AIxBIO

Beyond Static Predictions — AI for Protein Dynamics and Multi-Cell Models

The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?

Featuring

Gabriele Corso

Boltz

CEO

Built DiffDock and the Boltz open-source models reshaping drug discovery.

Peter Clark

Novo Nordisk

VP, CDD

Computational drug-design leader, shipped candidates from CAR-T to peptides.

Theofanis Karaletsos

Achira

Co-founder

Tanja Kortemme

UCSF

Vice Dean of Research

De novo protein-design pioneer; NIH Pioneer Award winner.

Elliot Hershberg

Amplify Partners

Partner, Author

Driving the Century of Biology

Breakout Session

3:30 PM

-

4:15 PM

AIxBIO

Beyond Static Predictions — AI for Protein Dynamics and Multi-Cell Models

The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?

Featuring

Gabriele Corso

Boltz

CEO

Built DiffDock and the Boltz open-source models reshaping drug discovery.

Peter Clark

Novo Nordisk

VP, CDD

Computational drug-design leader, shipped candidates from CAR-T to peptides.

Theofanis Karaletsos

Achira

Co-founder

Tanja Kortemme

UCSF

Vice Dean of Research

De novo protein-design pioneer; NIH Pioneer Award winner.

Elliot Hershberg

Amplify Partners

Partner, Author

Driving the Century of Biology

Master Class

3:00 PM

-

3:30 PM

AIxBIO

AIxBio Masterclass: With Boltz Model Creator Gabriele Corso

Join Boltz co-founder Gabriele Corso for an interactive, hands-on masterclass exploring how next-generation AI models are transforming molecular design, protein engineering, and therapeutic development. In this live workshop, attendees will step inside the Boltz platform to learn how structure-based generative modeling pipelines can be applied to real-world design challenges. Participants will see how AI-driven predictions are reshaping the drug discovery workflow — from identifying high-value molecular hits to optimizing binders, and therapeutic candidates. This session is designed for scientists, founders, and R&D leaders looking to understand how to actually use cutting-edge AI to accelerate biological innovation.

Featuring

Gabriele Corso

Boltz

CEO

Built DiffDock and the Boltz open-source models reshaping drug discovery.

Master Class

3:00 PM

-

3:30 PM

AIxBIO

AIxBio Masterclass: With Boltz Model Creator Gabriele Corso

Join Boltz co-founder Gabriele Corso for an interactive, hands-on masterclass exploring how next-generation AI models are transforming molecular design, protein engineering, and therapeutic development. In this live workshop, attendees will step inside the Boltz platform to learn how structure-based generative modeling pipelines can be applied to real-world design challenges. Participants will see how AI-driven predictions are reshaping the drug discovery workflow — from identifying high-value molecular hits to optimizing binders, and therapeutic candidates. This session is designed for scientists, founders, and R&D leaders looking to understand how to actually use cutting-edge AI to accelerate biological innovation.

Featuring

Gabriele Corso

Boltz

CEO

Built DiffDock and the Boltz open-source models reshaping drug discovery.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include